News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Repros Therapeutics Inc. Provides Additional Information on Proellex(R) Clinical Program
July 7, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics (NasdaqGM:RPRX) provides a further update on the clinical development of Proellex 25 and 12.5 mg doses.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
MORE ON THIS TOPIC
Drug Development
Five Trends That Got Everyone Talking in Pharma and Biotech This Year
November 12, 2025
·
5 min read
·
Jennifer Smith-Parker
MASH
Altimmune Poised for $1B+ Opportunity as MASH Drug Aces Phase IIb
November 12, 2025
·
2 min read
·
Tristan Manalac
Podcast
Pfizer Wins Metsera, Trump Strikes GLP-1 Pricing Deal, FDA Awards More Priority Vouchers
November 12, 2025
·
1 min read
·
Heather McKenzie
Cardiovascular disease
Amgen, Merck, Novo, More Take Cardiovascular Benefits to New Heights at AHA 2025
November 11, 2025
·
5 min read
·
Tristan Manalac
